We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.75% | 25.45 | 25.54 | 25.20 | 25.33 | 46,480,354 | 01:00:00 |
From Apr 2022 to Apr 2024
By Will Feuer
Zoetis Inc. cut its full-year adjusted earnings guidance and lowered the high-end of its range for sales, citing negative effects from recent changes to foreign-exchange rates.
The animal-medicine company, spun off by Pfizer Inc. in 2013, said it now expects adjusted earnings of between $4.97 a share and $5.05 a share, down from its prior guidance of $4.99 a share to $5.09 a share.
Full-year revenue is expected to be between $8.225 billion and $8.325 billion, narrowed from $8.225 billion to $8.375 billion. Unadjusted earnings are expected to be between $4.65 a share and $4.75 a share, narrowed from a range of $4.65 a share to $4.77 a share.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
August 04, 2022 07:51 ET (11:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
